Abstract

Background and AimsDespite the remarkable progress of metabolic dysfunction-associated fatty liver disease (MAFLD), formerly named non-alcoholic fatty liver disease (NAFLD), the disease remains poorly improved. Since increased oxidative stress and inflammation contribute to the initiation and progression of fatty liver disorders, vitamin C (VC), an antioxidant agent, might be a suitable treatment option for MAFLD. However, the lack of clinically confirmed benefits makes clinicians challenging to recommend antioxidant supplements for MAFLD individuals.MethodsHerein, the nationally representative National Health and Nutrition Examination Survey 2017–2018 data were collected to evaluate the potential association between the serum VC levels with the risk of different categories of NALFD and the newly proposed MAFLD terminology. Hepatic steatosis was defined as controlled attenuated parameter scores ≥ 263 dB/m, whereas liver fibrosis (LF) status was defined as F0–F4, with the cutoff values of median liver stiffness being 6.3, 8.3, 10.5, and 12.5 (KPa), respectively. A cross-sectional analysis was performed to calculate the odds rate and determine the potential beneficial effects of VC.ResultsA total of 4,494 participants aged more than 18 years and conducted transient elastography examinations were included. Our findings demonstrated that participants with increased serum VC status were more likely to be female predominant, more educated, and moderate drinkers. Interestingly, female participants tended to have a lower prevalence of NAFLD, MAFLD, LF, and liver cirrhosis (LC) after stratification by gender. Moreover, our results revealed that participants from the quartile three group (quartile 3: 50.5–67.0 μmol/L) experienced a slightly lower risk of MAFLD than the risk of NAFLD. Of note, the serum concentration of VC (quartile 2: 30.9–50.5 μmol/L) inversely associated with LF and LC was lower than the serum VC level (quartile 3) associated with NAFLD and MAFLD. Notably, individuals from the quartile 3 group experienced a statistically significant 32.5, 42.0, 45.7, and 71% decrease in risk of NAFLD, MAFLD, LF, and LC, respectively.ConclusionIn summary, our findings suggested an inverse association between serum VC levels and NAFLD, MAFLD, LF, or LC. Additionally, adjustment of VC supplementation according to age, gender, and ethnicity may be a promising candidate for these diseases.

Highlights

  • Non-alcoholic fatty liver disease (NAFLD) is a public health problem affecting approximately a quarter of the global population and has been the fastest-growing cause of liver cancer in the United States [1, 2]

  • Significant differences were observed in most outcomes across quartiles of serum vitamin C (VC) concentrations, except for hepatitis B virus (HBV) infection, aspartate aminotransferase (AST), and total bilirubin (TB) (p > 0.05)

  • The serum concentration of VC (Q2: 30.9–50.5 μmol/L) inversely associated with liver fibrosis (LF) and liver cirrhosis (LC) was lower than the serum VC level (Q3: 50.5–67.0 μmol/L) associated with NAFLD and metabolic dysfunction-associated fatty liver disease (MAFLD)

Read more

Summary

Introduction

Non-alcoholic fatty liver disease (NAFLD) is a public health problem affecting approximately a quarter of the global population and has been the fastest-growing cause of liver cancer in the United States [1, 2]. Despite remarkable progress, this condition remains poorly improved, and effective therapeutic strategies remain elusive. The proposed new term from NAFLD to MAFLD is not a change to a more appropriate name and a shift in the populations who meet the criteria for one but not the other. Despite the remarkable progress of metabolic dysfunction-associated fatty liver disease (MAFLD), formerly named non-alcoholic fatty liver disease (NAFLD), the disease remains poorly improved. The lack of clinically confirmed benefits makes clinicians challenging to recommend antioxidant supplements for MAFLD individuals

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.